MedTrace Logo

The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy

NCT00518817 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2007-08-21

No results posted yet for this study

Summary

This study will have significant impact on muscular dystrophy patients as it promotes early screening for heart disease. With early identification, beneficial medical therapy can be started sooner, resulting in restoring and maintaining normal heart function. This is critical to the survival of these patients. We have reported previously that heart failure in all patients may have common mechanisms, the "final common pathway". Heart failure is a significant health problem with 5 million people in the US carrying the diagnosis and accounting for 12-15 million office visits and 6.5 million hospital days per year. The number of deaths from heart failure continues to increase. The data from this study could impact patients worldwide with heart failure by offering new insight into an ever-growing disease population and lead to significant changes in how they are currently treated.

Conditions

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • John L Jefferies, MD · Baylor College of Medicine

  • Jeffrey A Towbin, MD · Baylor College of Medicine

Eligibility

Min Age
1 Month
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518817 on ClinicalTrials.gov